Alivus Life Sciences Limited — Investor Meet, 23-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alivus Life Sciences reported Q4 revenue of Rs.650 Cr, up 21% YoY, with a 32.1% EBITDA margin driven by better product mix, yielding PAT of Rs.142 Cr (22% margin). FY25 revenue grew 7.1% ex-PLI to Rs.2387 Cr, with CVS and CNS therapies contributing 55%. Management expects mid-teens volume growth but high single-digit revenue rise in FY26 due to pricing pressures; margins steady at 28-30%. CAPEX of Rs.550-600 Cr will fund expansions and a new R&D center. CDMO grew softly, picking up in H2 FY26 with upcoming products. Order pipeline is strong, especially in high-potent APIs and launches from FY28. US market softness reflects pricing erosion and destocking, but demand remains stable. Management stays confident on sustainable growth amid challenges.